sj-pdf-1-mso-10.1177_20552173211004634 - Supplemental material for Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS

Supplemental material, sj-pdf-1-mso-10.1177_20552173211004634 for Impact of natalizumab on quality of life in a real-world cohort of patients with multiple sclerosis: Results from MS PATHS by Carrie M Hersh Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV, USA Bernd Kieseier, Carl de Moor Biogen, Cambridge, MA, USA, at the time of these analyses Biogen, Cambridge, MA, USA Deborah M Miller Mellen Center, Cleveland Clinic Main Campus, Cleveland, OH, USA Denise Campagnolo, James R Williams Biogen, Cambridge, MA, USA Kathryn C Fitzgerald Department of Neurology, Johns Hopkins University, Baltimore, MD, USA Kuangnan Xiong Biogen, Cambridge, MA, USA, at the time of these analyses Marisa P McGinley Mellen Center, Cleveland Clinic Main Campus, Cleveland, OH, USA Megan Hyland Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA Richard A Rudick Biogen, Cambridge, MA, USA, at the time of these analyses Tjalf Ziemssen Department of Neurology, Multiple Sclerosis Center and Neuroimmunological Laboratory, University Clinic Carl-Gustav Carus, Dresden, Germany Irene Koulinska Biogen, Cambridge, MA, USA, at the time of these analyses in Multiple Sclerosis Journal – Experimental, Translational and Clinical